Stock Events

Stock Events

Rhythm Pharmaceuticals 

€90.50
48
+€0.00+0% Monday 15:30

Statistics

Day High
89.5
Day Low
89.5
52W High
103
52W Low
76.5
Volume
1
Avg. Volume
-
Mkt Cap
6.23B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q1 2026
Q2 2026
Next
-0.71
-0.68
-0.65
-0.63
Expected EPS
-0.6253866944
Actual EPS
N/A

Financials

-107.12%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
163.88MRevenue
-175.55MNet Income

Analyst Ratings

106.92Average Price Target
The highest estimate is 121.41.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy
82%
Hold
18%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1RV.XETRA. It's not an investment recommendation.
NVIDIA
12
NVDA
Apple
11
AAPL
Microsoft
11
MSFT
AMD
10
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novo Nordisk
NVO
Mkt Cap201.64B
Novo Nordisk offers treatments for obesity, a key area Rhythm Pharmaceuticals targets with their weight management drugs.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly has a portfolio of treatments for diabetes and obesity, directly competing with Rhythm's obesity-related therapies.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca develops medications for various metabolic disorders, including obesity, competing in the same therapeutic area as Rhythm.
Merck
MRK
Mkt Cap366B
Merck & Co. has a broad portfolio that includes treatments for metabolic disorders and obesity, making them a competitor.
Pfizer
PFE
Mkt Cap159.36B
Pfizer works on metabolic disorders and obesity treatments, areas that overlap with Rhythm Pharmaceuticals' focus.
Sanofi
SNY
Mkt Cap107.39B
Sanofi has a presence in the diabetes and obesity market, competing with Rhythm Pharmaceuticals' products.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline offers products for metabolic disorders, including obesity, competing in the same market as Rhythm.
AMGEN
AMGN
Mkt Cap233.78B
Amgen focuses on innovative treatments, including those for metabolic disorders, positioning them as a competitor.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals works on treatments for obesity and related metabolic disorders, making them a competitor.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals, while primarily known for cystic fibrosis treatments, is expanding into other areas, including metabolic disorders, potentially competing with Rhythm.

About

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Show more...
CEO
David Meeker
Employees
414
Country
United States
ISIN
US76243J1051
WKN
000A2H5A0

Listings

MU
DE
1RV.MU
STU
DE
1RV.STU
XETRA
DE
1RV.XETRA
XNAS
US
RYTM

0 Comments

Share your thoughts

FAQ

What is Rhythm Pharmaceuticals stock price today?▼
The current price of 1RV.XETRA is €90.50 EUR — it has increased by +0% in the past 24 hours. Watch Rhythm Pharmaceuticals stock price performance more closely on the chart.
What is Rhythm Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange Rhythm Pharmaceuticals stocks are traded under the ticker 1RV.XETRA.
What is Rhythm Pharmaceuticals market cap?▼
Today Rhythm Pharmaceuticals has the market capitalization of 6.23B
When is the next Rhythm Pharmaceuticals earnings date?▼
Rhythm Pharmaceuticals is going to release the next earnings report on November 10, 2026.
What were Rhythm Pharmaceuticals earnings last quarter?▼
1RV.XETRA earnings for the last quarter are -0.63 EUR per share, whereas the estimation was -0.7 EUR resulting in a +9.56% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Rhythm Pharmaceuticals revenue for the last year?▼
Rhythm Pharmaceuticals revenue for the last year amounts to 163.88M EUR.
What is Rhythm Pharmaceuticals net income for the last year?▼
1RV.XETRA net income for the last year is -175.55M EUR.
How many employees does Rhythm Pharmaceuticals have?▼
As of September 05, 2026, the company has 414 employees.
In which sector is Rhythm Pharmaceuticals located?▼
Rhythm Pharmaceuticals operates in the Health & Wellness sector.
When did Rhythm Pharmaceuticals complete a stock split?▼
Rhythm Pharmaceuticals has not had any recent stock splits.
Where is Rhythm Pharmaceuticals headquartered?▼
Rhythm Pharmaceuticals is headquartered in BOSTON, United States.